EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, CGEN: Compugen Ltd

24 Oct 25 15:59
LAST:

1.820

CHANGE:
 0.13		OPEN:
1.740		HIGH:
1.820		ASK:
4.200		VOLUME:
321.2K
CHG(%):
7.78		PREV:
1.670		LOW:
1.690		BID:
2.600		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Oct 251.7401.8201.6901.800333.4K
23 Oct 251.7601.7601.6401.670455.5K
22 Oct 251.8001.8001.6301.740612.8K
21 Oct 251.8301.8501.7201.760388.7K
20 Oct 251.9302.0001.8201.840715.6K
17 Oct 252.0002.0001.8101.875678.8K
16 Oct 252.0302.0901.9201.950808.3K
15 Oct 252.0802.1301.9902.060925.6K
14 Oct 252.2402.2502.0602.1101.17M
13 Oct 251.9802.3801.9322.2401.57M

COMPANY PROFILE

Name:Compugen Ltd
About:Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Sector:Healthcare
Industry:Biotechnology
Address:Azrieli Center, Holon, Israel, 5885849
Website:https://cgen.com
CUSIP:M25722105
CIK:0001119774
ISIN:IL0010852080
FIGI:BBG000B9ZLB0

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.763.3%
MA10:1.904.6%
MA20:1.800.9%
MA50:1.5715.9%
MA100:1.5914.8%
MA200:1.6510.0%
STO9:22.41
STO14:18.31 
RSI14:50.37
WPR14:-77.19
MTM14:0.04
ROC14:0.02 
ATR:0.18 
Week High:2.009.9%
Week Low:1.6311.7%
Month High:2.3830.8%
Month Low:1.3710.0%
Year High:2.6646.2%
Year Low:1.1361.1%
Volatility:3.63